プロトンポンプ阻害剤オメプラゾール合成

キラル選択化学による胃酸制御

Pharmaceutical & Drug Manufacturing Global Industrial Scale $3.5 billion

概要

Omeprazole is the first proton pump inhibitor (PPI) to reach the market and remains one of the most prescribed medications globally for treating gastric acid disorders, peptic ulcers, and GERD. The synthesis involves a multi-step process building the benzimidazole-pyridine core structure. The chiral version, esomeprazole (the S-enantiomer), represents a significant pharmaceutical advancement, produced using an asymmetric oxidation that won AstraZeneca substantial patent protection.

化学プロセス

2-Chloromethyl-3,5-dimethyl-4-methoxypyridine is coupled with 5-methoxy-2-mercaptobenzimidazole to form the thioether intermediate. Selective oxidation with m-CPBA or titanium-mediated asymmetric oxidation yields the sulfoxide drug substance.

Thioether intermediate + m-CPBA → Omeprazole (sulfoxide)
For esomeprazole: Ti(OiPr)₄/(R,R)-DET/cumene hydroperoxide → S-omeprazole (>99.5% ee)

原材料

  • 5-Methoxy-2-mercaptobenzimidazole — Multi-step synthesis from o-phenylenediamine (Core structure)
  • 2-Chloromethyl-3,5-dimethyl-4-methoxypyridine — Pyridine chemistry (Pyridine moiety)
  • m-CPBA (meta-chloroperoxybenzoic acid) — Chemical synthesis (Oxidizing agent)

最終製品

  • Omeprazole (C₁₇H₁₉N₃O₃S) — Proton pump inhibitor for GERD and ulcers (Racemic or enantiopure form)
<path stroke-linecap="round" stroke-linejoin="round" d="M12 9v3.75m-9.303 3.376c-.866 1.5.217 3.374 1.948 3.374h14.71c1.73 0 2.813-1.874 1.948-3.374L13.949 3.378c-.866-1.5-3.032-1.5-3.898 0L2.697 16.126zM12 15.75h.007v.008H12v-.008z" />

Environmental Impact

Multi-step synthesis generates significant organic waste including halogenated solvents. m-CPBA oxidation produces m-chlorobenzoic acid waste. Modern production increasingly uses catalytic oxidation methods and solvent recycling to minimize environmental impact.

安全性の考慮事項

最新のイノベーション

Biocatalytic oxidation using engineered cytochrome P450 enzymes and Baeyer-Villiger monooxygenases offers enantioselective sulfoxidation under mild conditions, potentially replacing chemical oxidants entirely.

生産規模

800

トン/年

$3.5 billion

市場価値

もっと見る Pharmaceutical & Drug Manufacturing

アモキシシリン半合成製造

Global Industrial Scale

イブプロフェン合成 — BHCグリーンプロセス

Global Industrial Scale

サリチル酸のアセチル化によるアスピリン合成

Global Industrial Scale

パラセタモール（アセトアミノフェン）合成

Global Industrial Scale

塩酸メトホルミン合成

Global Industrial Scale

発酵によるペニシリンG製造

Global Industrial Scale

組換えヒトインスリン製造

Global Industrial Scale

Frequently Asked Questions

What industry uses プロトンポンプ阻害剤オメプラゾール合成?
プロトンポンプ阻害剤オメプラゾール合成 is used in the pharmaceutical & drug manufacturing sector at global industrial scale scale.
What process is involved in プロトンポンプ阻害剤オメプラゾール合成?
2-Chloromethyl-3,5-dimethyl-4-methoxypyridine is coupled with 5-methoxy-2-mercaptobenzimidazole to form the thioether intermediate. Selective oxidation with m-CPBA or titanium-mediated asymmetric oxidation yields the sulfoxide drug substance.
What is the economic significance of プロトンポンプ阻害剤オメプラゾール合成?
プロトンポンプ阻害剤オメプラゾール合成 has a market value of $3.5 billion and annual production of 800 tons.
What is the environmental impact of プロトンポンプ阻害剤オメプラゾール合成?
Multi-step synthesis generates significant organic waste including halogenated solvents. m-CPBA oxidation produces m-chlorobenzoic acid waste. Modern production increasingly uses catalytic oxidation methods and solvent recycling to minimize environmental impact.
What raw materials are used in プロトンポンプ阻害剤オメプラゾール合成?
The main raw materials include: 5-Methoxy-2-mercaptobenzimidazole, 2-Chloromethyl-3,5-dimethyl-4-methoxypyridine, m-CPBA (meta-chloroperoxybenzoic acid).